EBOS Group
Market Cap
NZ$3.5b
Last Updated
2020/07/03 10:34 UTC
Data Sources
Company Financials +
Executive Summary
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia and New Zealand.
Rewards
Risk Analysis
Snowflake Analysis
Established dividend payer with proven track record.
Similar Companies
Share Price & News
How has EBOS Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EBO has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.4%
EBO
0.8%
NZ Healthcare
2.6%
NZ Market
1 Year Return
-7.7%
EBO
2.4%
NZ Healthcare
1.4%
NZ Market
Return vs Industry: EBO underperformed the NZ Healthcare industry which returned 2.4% over the past year.
Return vs Market: EBO underperformed the NZ Market which returned 1.4% over the past year.
Shareholder returns
| EBO | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.4% | 0.8% | 2.6% |
| 30 Day | -3.0% | 0.5% | 3.4% |
| 90 Day | -3.2% | 13.0% | 15.4% |
| 1 Year | -4.6%-7.7% | 4.9%2.4% | 6.0%1.4% |
| 3 Year | 38.9%24.9% | 41.4%30.6% | 41.5%19.9% |
| 5 Year | 154.0%112.6% | 86.8%65.8% | 94.0%42.0% |
Price Volatility Vs. Market
How volatile is EBOS Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Did You Participate In Any Of EBOS Group's (NZSE:EBO) Fantastic 160% Return ?1 month ago | Simply Wall St
Want To Invest In EBOS Group Limited (NZSE:EBO)? Here's How It Performed Lately1 month ago | Simply Wall St
An Intrinsic Calculation For EBOS Group Limited (NZSE:EBO) Suggests It's 41% UndervaluedValuation
Is EBOS Group undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EBO (NZ$21.79) is trading below our estimate of fair value (NZ$45.49)
Significantly Below Fair Value: EBO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EBO is poor value based on its PE Ratio (21.3x) compared to the Healthcare industry average (20.8x).
PE vs Market: EBO is poor value based on its PE Ratio (21.3x) compared to the NZ market (18.6x).
Price to Earnings Growth Ratio
PEG Ratio: EBO is poor value based on its PEG Ratio (2.5x)
Price to Book Ratio
PB vs Industry: EBO is overvalued based on its PB Ratio (2.6x) compared to the NZ Healthcare industry average (1.2x).
Next Steps
Future Growth
How is EBOS Group forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
8.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EBO's forecast earnings growth (8.6% per year) is above the savings rate (2.6%).
Earnings vs Market: EBO's earnings (8.6% per year) are forecast to grow faster than the NZ market (8.5% per year).
High Growth Earnings: EBO's earnings are forecast to grow, but not significantly.
Revenue vs Market: EBO's revenue (4.2% per year) is forecast to grow slower than the NZ market (6.1% per year).
High Growth Revenue: EBO's revenue (4.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EBO's Return on Equity is forecast to be low in 3 years time (13.7%).
Next Steps
Past Performance
How has EBOS Group performed over the past 5 years?
8.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EBO has high quality earnings.
Growing Profit Margin: EBO's current net profit margins (2%) are lower than last year (2%).
Past Earnings Growth Analysis
Earnings Trend: EBO's earnings have grown by 8.4% per year over the past 5 years.
Accelerating Growth: EBO's earnings growth over the past year (13.3%) exceeds its 5-year average (8.4% per year).
Earnings vs Industry: EBO earnings growth over the past year (13.3%) exceeded the Healthcare industry -18.8%.
Return on Equity
High ROE: EBO's Return on Equity (11.8%) is considered low.
Next Steps
Financial Health
How is EBOS Group's financial position?
Financial Position Analysis
Short Term Liabilities: EBO's short term assets (A$2.1B) exceed its short term liabilities (A$1.8B).
Long Term Liabilities: EBO's short term assets (A$2.1B) exceed its long term liabilities (A$816.2M).
Debt to Equity History and Analysis
Debt Level: EBO's debt to equity ratio (52.8%) is considered high.
Reducing Debt: EBO's debt to equity ratio has increased from 44% to 52.8% over the past 5 years.
Debt Coverage: EBO's debt is well covered by operating cash flow (22.6%).
Interest Coverage: EBO's interest payments on its debt are well covered by EBIT (8.5x coverage).
Balance Sheet
Next Steps
Dividend
What is EBOS Group current dividend yield, its reliability and sustainability?
3.36%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: EBO's dividend (3.36%) is higher than the bottom 25% of dividend payers in the NZ market (3.16%).
High Dividend: EBO's dividend (3.36%) is low compared to the top 25% of dividend payers in the NZ market (5.7%).
Stability and Growth of Payments
Stable Dividend: EBO's dividends per share have been stable in the past 10 years.
Growing Dividend: EBO's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (74.6%), EBO's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: EBO's dividends in 3 years are forecast to be covered by earnings (71.9% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.3yrs
Average management tenure
CEO
John Cullity
2.25yrs
Tenure
AU$1,638,031
Compensation
Mr. John Cullity has been Non-Executive Director of Terry White Group Limited since March 29, 2018. Mr. Cullity has been Chief Executive Officer of EBOS Group Limited since April 1, 2018. Mr. Cullity serve ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD1.13M) is about average for companies of similar size in the NZ market ($USD1.14M).
Compensation vs Earnings: John's compensation has increased by more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 2.25yrs | AU$1.64m | no data | |
| Acting CFO & Chief Accountant | 0.33yr | no data | 0.00020% A$6.9k | |
| Chief Information Officer | 5.5yrs | no data | no data | |
| Manager of Investor Relations | no data | no data | no data | |
| General Counsel | 5.5yrs | no data | no data | |
| Group General Manager of Human Recourses | 0.67yr | no data | no data | |
| Chief Executive Officer of Animal Care & Consumer Brands | 6yrs | no data | 0.031% A$1.1m | |
| Chief Executive Officer of Symbion | 2.5yrs | no data | no data | |
| Executive General Manager of Pharmacy & Institutional Healthcare | 4.08yrs | no data | no data |
3.3yrs
Average Tenure
Experienced Management: EBO's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman | 0.75yr | no data | 0.065% A$2.3m | |
| Director | 7yrs | no data | no data | |
| Independent Director | 13.83yrs | no data | 0.0071% A$245.1k | |
| Independent Director | 1yr | no data | 0.0013% A$43.7k | |
| Director | 7yrs | no data | no data | |
| Independent Director | 0.42yr | no data | no data |
4.0yrs
Average Tenure
Experienced Board: EBO's board of directors are considered experienced (4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
EBOS Group Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: EBOS Group Limited
- Ticker: EBO
- Exchange: NZSE
- Founded: 1922
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: NZ$3.467b
- Shares outstanding: 161.64m
- Website: https://www.ebosgroup.com
Number of Employees
Location
- EBOS Group Limited
- 737 Bourke Street
- Level 7
- Docklands
- Victoria
- 3008
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EBO | NZSE (New Zealand Stock Exchange) | Yes | Ordinary Shares | NZ | NZD | Jun 1999 |
| EBO | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Jun 1999 |
| EBO | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Jun 1999 |
| EBOS.Y | OTCPK (Pink Sheets LLC) | SPON ADR | US | USD | Nov 2011 |
Biography
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia and New Zealand. It operates in two segments, Healthcare and Animal Care. The company offers health logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and multi-brand retail pharmacy services. It also offers vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; community based health care services and programs; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a cost-effective community pharmacy banner that allows members drive their retail businesses. In addition, the company supplies health and wellness products public and private hospitals, day surgeries, general practice, aged care facilities, specialist clinics, government, and non-profit health agencies, as well as clinically essential products; produces educational materials, Websites, disease awareness and professional development programs; and pharmacy services to private and public hospitals, cancer centers, correctional facilities, and veterinary clinics. Further, it offers contract logistics services, such as healthcare distribution, warehousing, clinical trial management, and product registration services; and clinical trial logistics. Additionally, the company provides pet nutrition product, treats, clean-up products, grooming, and accessories; and wholesales veterinary products for companion animals, production animals, and equine athletes. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was founded in 1922 and is headquartered in Docklands, Australia.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/03 10:34 |
| End of Day Share Price | 2020/07/03 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.